Are 'breakthrough' Drugs As Safe As Other Fda-approved Medicines?

New research questions the quality of drugs given the "breakthrough therapy" designation by the US Food and Drug Administration. In late 2012, the FDA created this designation to speed the process for reviewing not-yet-approved experimental medicines intended to treat serious or life-threatening conditions.

Topics:  us food   drug   administration   fda   breakthrough   medicines   designation   
BING NEWS:
  • The Time Is Now For Federal Reform Of Direct-To-Consumer Advertising Of Prescription Drugs
    Hundreds of thousands of families and friends are now, tragically, members of a community formed around a loved one’s chemical dependency or loss—a community that began with a drug that was marketed ...
    04/30/2024 - 1:00 pm | View Link
  • DEA’s Psychedelic-Outlawing Effort Attacked by Private Industry
    Despite the U.S. Food and Drug Administration’s (FDA) approval of depression treatment drug Esketamine and conferring of breakthrough therapy status on other psychedelics, the DEA is amping up its ...
    04/29/2024 - 2:30 am | View Link
  • 164 Active Trials Are Testing Alzheimer’s Therapeutics
    And on the heels of newly FDA-approved drugs Aduhelm® (aducanumab ... “The pipeline of potential new Alzheimer’s treatments is diverse, offering a future with new, safe, and effective treatments and ...
    04/24/2024 - 1:00 pm | View Link
  • ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
    ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus ...
    04/22/2024 - 2:55 pm | View Link
  • Kura Oncology, Inc.: Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
    Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML - - Registration-directed trial of ziftomenib in NPM1-mutant AML on track to comple ...
    04/22/2024 - 2:53 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Health News